ImmunoGen, Inc.
Biotechnology
Waltham, Massachusetts
Public Corporation
Our Company
ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor a-positive ovarian cancers and other solid tumors. Leading healthcare companies have licensed rights to use ImmunoGen's technology to develop novel anticancer therapies, and Roche's marketed product, Kadcyla, utilizes ImmunoGen's ADC technology.Skills We're Looking For
Analytics
Assessments
Design
Equipment
Leading Cross-Functional Teams
Manufacturing
Process Development
Project Management
Technical Support
Visual
Equipment Selection
Pharmaceutical
